novaMETABOLISM Combo

PROBIOTIC COMBINATION FOR THE MANAGEMENT OF PRE-DIABETES CONDITION & METABOLIC SYNDROME

B. psychraerophilum Q5 (DSM 33131) L. hordei KLL19 (DSM 33127)
L. harbinensis G8 (DSM 33126)

Recommended dosage: 7 billion cells per day

Scientifica Data

Probiotics were investigated in an in vitro diabetic model, with regard to hyperglycemia, insulin resistance, hypercholesterolemia and dyslipidemias. In particular, the following were analyzed:

• analysis of cytotoxicity and production of reactive oxygen species;
• quantification of glucose and insulin to analyze insulin resistance;
• the main markers involved in glucose metabolism (such as AKT, GLUT4 and PGC-1). To better understand the effect, after the first screening the most effective combinations were studied in a complete metabolic model, including the intestinal passage up to the metabolic effect on the liver:
• evaluation of liver damage;
• analysis of free cholesterol levels;
• lipids accumulation and circulating LDL;
• cholesterol biosynthesis and metabolism (AMPK, PCSK9, SREBP2 and LDLr);
• hepatic metabolism, focusing on the main isoforms of CYP450;
• inflammatory picture and pro-inflammatory cytokines analysis

Results

The combination of the three next generation probiotics showed an amplified positive effect (p<0.05) on intestinal and hepatic metabolism. Remarkably, the combo resulted to significantly (p<0.05 vs control) reduce the lipid accumulation. All data and reports are available, please contact us to receive more information. Here it is reported the global effect of probiotics combination on the in vitro diabetic model:

PROBIOTICS COMBO EFFECT VARIATION VS REFERENCE